ESMO2023: Phase I open-label, dose escalation and expansion study of YH003 in combination with Toripalimab in patients with advanced solid tumors
Conclusions YH003 was well tolerated up to 1.0 mg/kg dose levels when combined with Toripalimab. Based on the safety, efficacy and PK data of YH003002,…
Read more
Preclinical Application of a Fully Human TCR-mimic Antibody Developed to Target NY-ESO-1/HLA-A02
SUMMARY Biocytogen’s TCRm antibody discovery platform combines unique immune technology with a multiplex screening method to obtain a high-affinity NY-ESO-1/HLA-A02 antibody, which can bind and…
Read more
Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMab mice
SUMMARY We identified TCR-mimic antibodies specific for KRAS G12V residues 7-16 complexed with HLA-A03 or HLA-A11. Both anti-KRAS G12V/HLA-A11 and anti-KRAS G12V/HLA-A03 antibodies showed abundant…
Read more
Fc-Competent Fully Human Anti-TIGIT Blocking Monoclonal Antibodies Demonstrated Potent Anti-Tumor Efficacy in Preclinical Models
SUMMARY We obtained novel, differentiating, fully human anti-TIGIT clones with the following properties and activities: • High binding affinity • Distinct epitopes from several clinical…
Read more
SITC 2023: BSA01, a Bispecific Antibody-drug Conjugate Targeting EGFR and Membrane-bound MUC1-C, Exhibits Anti-tumor Efficacy In Vivo Efficacy Against Triple-negative Breast Cancer Xenografts
SUMMARY Co-expression of EGFR and MUC1 in multiple solid tumors suggests that simultaneous targeting of EGFR and MUC1 with bsADC has the potential to enhance…
Read more
SITC 2023: A Novel Bispecific Antibody-drug Conjugate Targeting PTK7 and TROP2, BCG033, Demonstrates Preclinical Efficacy Against Triple-negative Breast Cancer Xenografts
SUMMARY PTK7 and TROP2 are two tumor-associated antigens (TAAs) highly expressed in TNBC and other solid tumors. The PTK7 x TROP2 bsAbs showed enhanced internalization…
Read more
SITC 2023: BCG022: A HER3×MET Bispecific Antibody-drug Conjugate (BsADC) Targeting Key Mechanisms of Bypass Resistance in Multiple Tumor Types
SUMMARY HER3 and MET were co-expressed in various tumor types, and their signaling plays a key role in EGFR TKI drug resistance. HER3×MET bsAbs generated…
Read more
SITC 2023: *DM005, an EGFR х MET Bispecific Antibody-drug Conjugate With a Novel DNA Topoisomerase I Inhibitor Payload, Showed Robust Anti-tumor Activity in Preclinical Models
SUMMARY • DM005 is a novel bsADC that targets EGFR and MET with a novel DNA topoisomerase I inhibitor payload. EGFR and MET are co-expressed…
Read more
SITC 2023: Preclinical Evaluation of Fully Human Bispecific Antibody-drug Candidates Targeting HER3 and the Juxtamembrane Region of MUC1
SUMMARY HER3 and MUC1 are co-expressed in a variety of solid tumors, including those with the high mortalities, making them excellent bsAb targets. DM002 bsAb…
Read more
SITC 2023: DM001, a Novel TROP2xEGFR Bispecific ADC, Demonstrates Potent Tumor Growth Inhibition in Preclinical Models and Favorable Safety Profile in Cynomolgus Monkey
SUMMARY EGFR and TROP2 are extensively co-expressed in many solid tumors, allowing dual targeting them with bsADCs. DM001 bsADCs simultaneous targeting both EGFR and TROP2…
Read more